Are we looking at cancer vaccine trials the wrong way?

Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient's immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment.

In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way?

“Cancer Vaccines: Moving Beyond Current Paradigms,” Jeffrey Schlom, et. al., Clinical Cancer Research, July 1, 2007, Volume 13, No. 13, pages 3776-3782.

In a review of five prostate cancer vaccine trials, NCI researchers offer evidence that patients who receive vaccines may respond better to subsequent chemotherapy or hormone treatment. The specific results – or endpoints – of these clinical trials, however, were not the long term survival of patients, but rather the degree to which the vaccine caused tumors to shrink. According to the researchers, since they didn't achieve their primary endpoints, these vaccines may be abandoned as dead-ends, despite their real therapeutic value in terms of prolonging patient survival.

“Clinical data are providing evidence that patients are living longer following vaccination, de-spite the fact that trials do not show the vaccines can induce the immune system into shrinking tumors,” said Jeffrey Schlom, Ph.D., chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute. “The data suggests that the scientific community and regulatory committees ought to rethink the design of clinical vaccine trials and our current approach to measuring the effectiveness of a cancer vaccine.”

According to the researchers, it may be more helpful to think of the effectiveness of a vaccine in terms of the response of the patient, rather than the response of the tumor. While the Response Criteria in Solid Tumors (RECIST) experimental standards works well in evaluating therapies that are toxic to tumors, such as radiation or chemotherapy, they are less capable of measuring the more subtle systemic effects of immune response, Schlom said.

While there is no conclusive evidence to explain why a vaccine may lead to better patient sur-vival, Schlom believes the evidence suggests that vaccines are, in fact, priming the immune sys-tem. “Vaccines are not passive, they induce a dynamic process of immune response that, in many cases may keep the tumor in check and enhance the effectiveness of subsequent therapies,” Schlom said.

About Therapeutic Cancer Vaccines

Unlike preventative vaccines, like those that protect against human papillomavirus or the flu, therapeutic cancer vaccines are given in the hopes of treating an existing disease. These cancer vaccines generally fall into two categories: cell-based, where vaccines are created using cells from the patient's own immune system that have been activated to the presence of cancer antigens and delivered back to the patient along with additional proteins that facilitate immune activation; and vector-based, where an engineered virus, or vector, is used to introduce cancer proteins and other molecules to stimulate the immune system. Both approaches are designed to rile the patient's immune system into attacking tumor cells.
In their review Schlom and his colleagues looked at two cell-based vaccines, Sipuleucel-T (Provenge) and GVAX, as well as three trials using an engineered pox-virus vector. While this review article focuses on prostate cancer vaccines, the researchers consider these trials as exam-ples of ongoing progress in similar vaccine therapies for lymphoma, melanoma, pancreatic, lung and other types of cancer.